Sana Biotechnology Inc (NASDAQ: SANA) stock jumped 2.38% on Monday to $4.30 against a previous-day closing price of $4.20. With 1.38 million shares changed hands, the volume of the stock remained heavier than its average volume of 1.24 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $4.5050 whereas the lowest price it dropped to was $4.1500. The 52-week range on SANA shows that it touched its highest point at $8.01 and its lowest point at $2.74 during that stretch. It currently has a 1-year price target of $8.80. Beta for the stock currently stands at 1.22.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of SANA was up-trending over the past week, with a rise of 23.56%, but this was up by 40.52% over a month. Three-month performance dropped to -23.21% while six-month performance fell -42.90%. The stock lost -8.12% in the past year, while it has gained 8.86% so far this year. A look at the trailing 12-month EPS for SANA yields -1.44 with Next year EPS estimates of -1.11. For the next quarter, that number is -0.38. This implies an EPS growth rate of 14.37% for this year and 28.08% for next year.
Float and Shares Shorts:
At present, 191.02 million SANA shares are outstanding with a float of 98.87 million shares on hand for trading. On Oct 30, 2023, short shares totaled 22.37 million, which was 11.35% higher than short shares on Sep 28, 2023. In addition to Dr. Steven D. Harr M.D. as the firm’s President, CEO & Director, Dr. Richard C. Mulligan Ph.D. serves as its Executive Vice Chairman & Head of Innovation Research.
Through their ownership of 92.79% of SANA’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 44.83% of SANA, in contrast to 29.43% held by mutual funds. Shares owned by individuals account for 19.35%. As the largest shareholder in SANA with 5.18% of the stake, Baillie Gifford & Co. holds 10,204,375 shares worth 10,204,375. A second-largest stockholder of SANA, Canada Pension Plan Investment Bo, holds 10,175,000 shares, controlling over 5.17% of the firm’s shares. Fidelity Management & Research Co is the third largest shareholder in SANA, holding 9,269,892 shares or 4.71% stake. With a 5.17% stake in SANA, the Canada Pension Plan is the largest stakeholder. A total of 10,175,000 shares are owned by the mutual fund manager. The Scottish Mortgage Investment Trus, which owns about 2.84% of SANA stock, is the second-largest Mutual Fund holder. It holds 5,586,264 shares valued at 16.54 million. Vanguard Total Stock Market ETF holds 1.51% of the stake in SANA, owning 2,968,610 shares worth 8.79 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for SANA since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With SANA analysts setting a high price target of $13.00 and a low target of $5.00, the average target price over the next 12 months is $8.80. Based on these targets, SANA could surge 202.33% to reach the target high and rise by 16.28% to reach the target low. Reaching the average price target will result in a growth of 104.65% from current levels.
Summary of Insider Activity:
Insiders traded SANA stock several times over the past three months with 0 Buys and 6 Sells. In these transactions, 0 shares were bought while 11,781,275 shares were sold. The number of buy transactions has increased to 6 while that of sell transactions has risen to 14 over the past year. The total number of shares bought during that period was 22,665 while 12,530,275 shares were sold.